Enki

Isomorphic Labs raises $5B to take AI drugs to trials

By

Published

Reporting from Bloomberg, TechCrunch

Isomorphic Labs raised a $5B Series C on Nov 17, led by Greenoaks and Sequoia, to push its AI-designed drugs toward first human trials.

What it means for founders

  • You cannot rent this engine. President Max Jaderberg said on November 2 that Isomorphic sells no model access, tokens or APIs. IsoDDE came out as a technical report without code or weights. OpenAI is moving in too, with its Orchestra Bio purchase.
  • Headline totals hide a thin early market. This single round is worth about 3.8 billion pounds, more than the 2.8 billion pounds the whole UK biotech sector raised in venture money through September. The BioIndustry Association says megadeals now dominate the headline totals and hide how hard early-stage companies still find it to raise.
  • Pharma pays on milestones. McKinsey figures cited by R&D World show the top 20 drugmakers paid only 2% of 2025 AI deal value at signing, with 60% to 90% riding on later trial and sales milestones. Plan your runway around that structure.

What we don't know yet

The final valuation, how much Alphabet invested, which candidate goes first and whether any patient gets dosed before the year ends, six weeks from now.

The story

Isomorphic Labs, the AI drug design company Google DeepMind spun out in 2021, unveiled a $5 billion Series C on November 17, with Greenoaks and Sequoia Capital as co-leads. The cash is meant to carry its first drug candidates into clinical trials, and none of them has yet been tested in a person.

Who invested in Isomorphic's $5B Series C

Andreessen Horowitz joined as a new backer with several unnamed others, and Alphabet, which owned at least 75% as of June per filings R&D World cited, invested again. Every earlier investor came back: the UK Sovereign AI Fund, Temasek, Thrive Capital, MGX, CapitalG and GV. Isomorphic gave no valuation. Bloomberg reported on November 4 that unnamed sources put the round near $50 billion in valuation.

This is the first raise since Demis Hassabis gave up the Google DeepMind CEO job in August. He now chairs DeepMind, serves as Alphabet's chief scientist and still runs Isomorphic. DeepMind keeps shipping its own biology models, most recently AlphaGenome 2.

How the round compares with Isomorphic's Series B

Isomorphic took its first outside money, $600 million, in March 2025, then $2.1 billion in a May 2026 Series B that Thrive Capital led. Adding this round, European Biotechnology counts $7.7 billion raised across three rounds. R&D World reported that BioSpace ranks it as biotech's largest venture round ever, ahead of the $3 billion Altos Labs launched with in 2022.

What the $5 billion pays for

Isomorphic will keep developing IsoDDE, its in-house drug design engine, which bundles simulation models that work across disease areas and drug types. It also plans a partner network for disease research and the clinical development infrastructure trials need. Hassabis told Bloomberg the company will move past small molecules into large-molecule biologics and has more than 20 programs running, TNW reported. "What we're trying to build is a platform to do hundreds of drugs a year," he said. Its drugmaker partners include Novartis, Johnson & Johnson and Eli Lilly.

When will Isomorphic start clinical trials?

In January at Davos, Hassabis said he expected trials to start by late 2026, R&D World noted. He declined to give Bloomberg a new date, saying regulatory filings are on track and more news will come in 2027. Isomorphic calls its preclinical results in cancer and immune disease positive, but the release includes no data on any candidate.

Sources

More in Funding & Business

How Enki covers newsCorrectionsReport an error